Univariate and multivariate analyses of the factors associated with platelet engraftment
| Variable . | n . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Group | .035 | .015 | |||||
| Control group | 60 | 1 | 1 | ||||
| rhTPO group | 59 | 1.573 | 1.031-2.4 | 1.696 | 1.108-2.597 | ||
| Age, y | .290 | ||||||
| <27 | 59 | 1 | |||||
| ≥27 | 60 | 0.797 | 0.524-1.213 | ||||
| Weight, kg | .139 | ||||||
| <57 | 58 | 1 | |||||
| ≥57 | 61 | 0.729 | 0.479-1.108 | ||||
| Patient sex | .683 | ||||||
| Female | 59 | 1 | |||||
| Male | 60 | 0.917 | 0.603-1.392 | ||||
| Donor-recipient sex | .888 | ||||||
| Female-male | 28 | 1 | |||||
| Others | 91 | 1.036 | 0.634-1.692 | ||||
| Disease risk index | |||||||
| Low | 7 | 1 | |||||
| Intermediate | 71 | 0.952 | 0.409-2.214 | .909 | |||
| High | 37 | 0.800 | 0.329-1.945 | .623 | |||
| Very high | 4 | 0.510 | 0.103-2.528 | .409 | |||
| Conditioning regimen | .002 | .001 | |||||
| TBI based | 18 | 1 | 1 | ||||
| BU-CY2 based | 101 | 3.639 | 1.583-8.365 | 4.082 | 1.764-9.446 | ||
| ABO compatibility | |||||||
| Identical | 1 | ||||||
| Minor incompatibility | 42 | 1.189 | 0.704-2.007 | .517 | |||
| Major incompatibility | 27 | 0.854 | 0.470-1.552 | .576 | |||
| Bidirectional incompatibility | 16 | 1.310 | 0.658-2.611 | .442 | |||
| TNC dose, ×107/kg | .026 | .134 | |||||
| <2.71 | 59 | 1 | 1 | ||||
| ≥2.71 | 60 | 1.615 | 1.06-2.461 | 1.391 | 0.904-2.141 | ||
| CD34+dose, ×105/kg | .004 | .013 | |||||
| <1.6 | 59 | 1 | 1 | ||||
| ≥1.6 | 60 | 1.884 | 1.228-2.892 | 1.743 | 1.122-2.708 | ||
| HLA matched | |||||||
| ≤4/6 | 77 | 1 | |||||
| 5/6 | 39 | 1.032 | 0.656-1.622 | .892 | |||
| 6/6 | 3 | 1.179 | 0.369-3.774 | .781 | |||
| Variable . | n . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | ||
| Group | .035 | .015 | |||||
| Control group | 60 | 1 | 1 | ||||
| rhTPO group | 59 | 1.573 | 1.031-2.4 | 1.696 | 1.108-2.597 | ||
| Age, y | .290 | ||||||
| <27 | 59 | 1 | |||||
| ≥27 | 60 | 0.797 | 0.524-1.213 | ||||
| Weight, kg | .139 | ||||||
| <57 | 58 | 1 | |||||
| ≥57 | 61 | 0.729 | 0.479-1.108 | ||||
| Patient sex | .683 | ||||||
| Female | 59 | 1 | |||||
| Male | 60 | 0.917 | 0.603-1.392 | ||||
| Donor-recipient sex | .888 | ||||||
| Female-male | 28 | 1 | |||||
| Others | 91 | 1.036 | 0.634-1.692 | ||||
| Disease risk index | |||||||
| Low | 7 | 1 | |||||
| Intermediate | 71 | 0.952 | 0.409-2.214 | .909 | |||
| High | 37 | 0.800 | 0.329-1.945 | .623 | |||
| Very high | 4 | 0.510 | 0.103-2.528 | .409 | |||
| Conditioning regimen | .002 | .001 | |||||
| TBI based | 18 | 1 | 1 | ||||
| BU-CY2 based | 101 | 3.639 | 1.583-8.365 | 4.082 | 1.764-9.446 | ||
| ABO compatibility | |||||||
| Identical | 1 | ||||||
| Minor incompatibility | 42 | 1.189 | 0.704-2.007 | .517 | |||
| Major incompatibility | 27 | 0.854 | 0.470-1.552 | .576 | |||
| Bidirectional incompatibility | 16 | 1.310 | 0.658-2.611 | .442 | |||
| TNC dose, ×107/kg | .026 | .134 | |||||
| <2.71 | 59 | 1 | 1 | ||||
| ≥2.71 | 60 | 1.615 | 1.06-2.461 | 1.391 | 0.904-2.141 | ||
| CD34+dose, ×105/kg | .004 | .013 | |||||
| <1.6 | 59 | 1 | 1 | ||||
| ≥1.6 | 60 | 1.884 | 1.228-2.892 | 1.743 | 1.122-2.708 | ||
| HLA matched | |||||||
| ≤4/6 | 77 | 1 | |||||
| 5/6 | 39 | 1.032 | 0.656-1.622 | .892 | |||
| 6/6 | 3 | 1.179 | 0.369-3.774 | .781 | |||